RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Decoding the crosstalk between ubiquitination and other post-translational modifications in cancer immunity: from mechanisms to clinical prospects.
Decoding the crosstalk between ubiquitination and other post-translational modifications in cancer immunity: from mechanisms to clinical prospects.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
肿瘤微环境受到复杂的翻译后修饰(PTMs)的动态调控,这些修饰在癌症免疫中发挥关键作用。泛素化与其他PTMs(如磷酸化、糖基化和乙酰化)共同协调免疫检查点活性和免疫细胞功能,塑造抗肿瘤应答。在本综述中,我们讨论泛素化与其他PTMs在癌症免疫中的复杂串扰和调控机制。研究揭示,免疫检查点蛋白(如PD-L1)的稳定性和功能受到协同或竞争性修饰的动态调控,这直接塑造了肿瘤微环境的免疫学特征。我们重点阐述PTMs如何调控TME中免疫细胞功能(如T细胞、NK细胞和巨噬细胞)以及关键信号通路(如STAT、I型IFN和NF-κB)。此外,我们总结靶向这些PTMs的潜在治疗策略,包括小分子抑制剂和新技术(如PROTACs和细胞穿透肽),为克服免疫治疗耐药和优化联合治疗提供见解。未来研究应探索非经典PTMs并利用多组学方法以完善精准免疫治疗策略。
The tumor microenvironment is dynamically regulated by complex post-translational modifications (PTMs), which play pivotal roles in cancer immunity. Ubiquitination, along with other PTMs such as phosphorylation, glycosylation, and acetylation, orchestrates immune checkpoint activity and immune cell function, shaping antitumor responses.
In this review, we discuss the intricate crosstalk and regulatory mechanisms between ubiquitination and other PTMs in cancer immunity. Studies have revealed that the stability and function of immune checkpoint proteins, such as PD-L1, are dynamically regulated by synergistic or competitive modifications, which directly shape the tumor microenvironment's immunological characteristics.
We highlight how PTMs regulate immune cell function (e. g. , T cells, NK cells, and macrophages) and key signaling pathways (e. g. , STAT, type I IFN, and NF-κB) in the TME.
Furthermore, we summarize potential therapeutic strategies targeting these PTMs, including small-molecule inhibitors and novel technologies (e. g. , PROTACs and cell-penetrating peptides), which offer insights into overcoming immunotherapy resistance and optimizing combination therapies. Future research should explore non-classical PTMs and leverage multi-omics approaches to refine precision immunotherapy strategies.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。